• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    HH&L Acquisition Co. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8/9/23 6:04:52 AM ET
    $HHLA
    Medical Specialities
    Health Care
    Get the next $HHLA alert in real time by email
    0001824185 false 00-0000000 0001824185 2023-08-08 2023-08-08 0001824185 HHLA:ClassOrdinarySharesParValue0.0001PerShareMember 2023-08-08 2023-08-08 0001824185 HHLA:RedeemableWarrantsEachWholeWarrantExercisableForOneClassAOrdinaryShareAtAnExercisePriceOf11.50PerShareMember 2023-08-08 2023-08-08 0001824185 HHLA:UnitsEachConsistingOfOneClassOrdinaryShareAndOnehalfOfOneRedeemableWarrantMember 2023-08-08 2023-08-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(D)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): August 9, 2023 (August 8, 2023)

     

    HH&L Acquisition Co.
    (Exact name of registrant as specified in its charter)

     

    Cayman Islands   001-40006   N/A
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification No.)

     

    Suite 2001-2002, 20/F, York House

    The Landmark, 15 Queen’s Road Central

    Central, Hong Kong 00000

    (Address of principal executive offices, including zip code)

     

    (852) 3752 2870

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Class A ordinary shares, par value $0.0001 per share   HHLA   The New York Stock Exchange
    Redeemable warrants, each whole warrant exercisable for one Class A ordinary share, each at an exercise price of $11.50 per share   HHLA WS   The New York Stock Exchange
    Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant   HHLA.U   The New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

      

     

      

     

     

    Item 1.01 Entry into a Material Definitive Agreement

     

    On August 8, 2023, HH&L Investment Co. (the “Sponsor”), the sponsor of HH&L Acquisition Co. (the “Company”), and the Company, entered into an subscription agreement (the “Subscription Agreement”) with Polar Multi-Strategy Master Fund (“Polar”), an unaffiliated third party of the Company, pursuant to which Polar agrees to make certain capital contributions (the “Investor Capital Contribution”) from time to time, at the request of the Sponsor, subject to the terms and conditions of the Subscription Agreement, to the Sponsor to meet the Sponsor’s commitment to fund the Company’s working capital needs. In exchange for the commitment of Polar to provide the Investor Capital Contribution, (i) the Company will issue certain Class A ordinary share of the Company to Polar at the closing of the business combination, as further described below; and (ii) upon repayment of working capital loans by the Company, the Sponsor will return the Investor Capital Contribution at the closing of the business combination, as further described below.

     

    Investor Capital Contribution

     

    The maximum aggregate Investor Capital Contribution is US$1,500,000, with (i) an initial Investor Capital Contribution of US$500,000 available for drawdown within five (5) business days of the Subscription Agreement; (ii) an Investor Capital Contribution of US$500,000 available for drawdown within five (5) business days after the date that the Company announces a business combination agreement; and (iii) an Investor Capital Contribution of US$500,000 available for drawdown after the date of a filing of a registration statement in relation to the business combination.

     

    Share Issuance

     

    In exchange for the forgoing commitment of Polar to make capital contributions to the Sponsor, the Company agrees to, or cause the surviving entity following the closing of the Company’s initial business combination to, issue one share of Class A Ordinary Shares of the Company for each dollar of Investor Capital Contribution funded by Polar (the “Subscription Shares”). The Company or the surviving entity of the business combination shall promptly file a registration statement to register the Subscription Shares after the closing of the business combination, but no later than thirty (30) calendar days after the closing of business combination, and cause the registration statement to be declared effective by ninety (90) calendar days after the closing of business combination.

     

    Return of Capital

     

    Upon repayment of working capital loans from the Company to the Sponsor, the Sponsor shall pay to Polar an amount equal to the Investor Capital Contribution actually funded and received by the Sponsor within five (5) business days of the closing of the business combination. The Sponsor shall not sell, transfer, or otherwise dispose of any securities owned by the Sponsor until the full amount of the Investor Capital Investment has been paid to Polar. The SPAC and Sponsor shall be jointly and severally obligated for such repayment. If the Company consummates its business combination, Polar may elect at closing of the business combination to receive such repayments of the Investor Capital Investment either in cash or in the form of Class A Ordinary Share of the Company at a rate of one Class A Ordinary Share for each US$10 of the Investor Capital Investment.

     

    If the Company liquidates without consummating any business combination, any amounts remaining in the Sponsor or the Company’s cash accounts outside of the Company’s trust account, to the extent legally permissible and permissible under agreements which Sponsor or the Company is party to, will be paid to Polar by the Sponsor within five (5) calendar days of the liquidation. Such payment from the Sponsor shall fulfill the Company and the Sponsor’s joint obligations to repay the Investor Capital Investment and release the Company and the Sponsor from any and all joint obligations to repay the Investor Capital Investment pursuant to the Subscription Agreement.

     

    The foregoing summary of the Subscription Agreement does not purport to be complete and is qualified in its entirety by reference to the Subscription Agreement attached hereto as Exhibit 10.1 and incorporated herein by reference.

     

     

     

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
         
    10.1   Subscription Agreement dated August 8, 2023 by and among HH&L Investment Co., HH&L Acquisition Co. and Polar Multi-Strategy Master Fund
         
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document). 

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      HH&L ACQUISITION CO.
         
         
      By: /s/ Richard Qi Li
      Name:    Richard Qi Li
      Title: Chief Executive Officer and Director
    Date: August 9, 2023    

     

     

     

    Get the next $HHLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HHLA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HHLA
    SEC Filings

    See more
    • SEC Form 25-NSE filed by HH&L Acquisition Co.

      25-NSE - HH&L Acquisition Co. (0001824185) (Subject)

      2/23/24 10:50:57 AM ET
      $HHLA
      Medical Specialities
      Health Care
    • HH&L Acquisition Co. filed SEC Form 8-K: Other Events

      8-K - HH&L Acquisition Co. (0001824185) (Filer)

      2/7/24 11:57:39 AM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form PRE 14A filed by HH&L Acquisition Co.

      PRE 14A - HH&L Acquisition Co. (0001824185) (Filer)

      1/23/24 5:14:45 PM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by HH&L Acquisition Co.

      SC 13G - HH&L Acquisition Co. (0001824185) (Subject)

      2/14/24 5:09:41 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by HH&L Acquisition Co.

      SC 13G - HH&L Acquisition Co. (0001824185) (Subject)

      2/13/24 8:00:58 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by HH&L Acquisition Co. (Amendment)

      SC 13G/A - HH&L Acquisition Co. (0001824185) (Subject)

      2/12/24 4:26:19 PM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Highbridge Capital Management Llc sold $2,687,500 worth of Class A Ordinary Shares (250,000 units at $10.75) (SEC Form 4)

      4 - HH&L Acquisition Co. (0001824185) (Issuer)

      1/12/24 4:15:16 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form 3: New insider Highbridge Capital Management Llc claimed ownership of 500,000 units of Class A Ordinary Shares

      3 - HH&L Acquisition Co. (0001824185) (Issuer)

      8/15/23 4:30:21 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • SEC Form 4 filed by HH&L Investment Co.

      4 - HH&L Acquisition Co. (0001824185) (Issuer)

      5/19/21 11:16:35 AM ET
      $HHLA
      Medical Specialities
      Health Care

    $HHLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DiaCarta Receives Accreditation by the College of American Pathologists (CAP)

      PLEASNTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that it has received accreditation by the College of American Pathologists (CAP) for its CLIA certified lab. This accreditation is awarded to facilities that meet the high standards of quality, accuracy, and consistency in laboratory services required by CAP and underscores DiaCarta's leadership and commitment to excellence. "This CAP Accreditation is a tremendous accomplishment that signifies DiaCarta's commitment to excellence and I am proud of our team's dedication in support this major milestone," said Zheng 

      5/9/23 5:51:25 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023

      Abstracts demonstrating XNA technology's improvements to assay sensitivity across different technology platforms and support for use in companion diagnostics (CDx) assay developmentAdditional abstracts to further support XNA technology's potential for use in minimal residual disease (MRD) monitoring of residual cancer cells PLEASANTON, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a precision molecular diagnostics company, today announced that it will present five data posters at the American Association of Cancer Research (AACR) Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023. The presentations will focus on how XNA can be used to

      4/16/23 2:00:00 PM ET
      $HHLA
      Medical Specialities
      Health Care
    • DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit

      PLEASANTON, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. ("DiaCarta"), a precision molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its QuantiVirusTM MPXV test, which is a PCR test for the qualitative detection of DNA from monkeypox virus (MPXV) in lesion swabs collected from individuals suspected of monkeypox infection. The test is designed for use by authorized laboratories on the most popular qPCR instruments, including the Thermo Fisher (ABI) QuantStudio5, Thermo Fisher (ABI) 7500 Fast Dx, Bio-Rad CFX384, and Roche LightCycler 480 II Systems. QuantiVirusTM MPXV test targets two di

      1/12/23 8:30:00 AM ET
      $HHLA
      Medical Specialities
      Health Care